Αποτελέσματα Αναζήτησης
7 Νοε 2022 · The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to...
8 Ιαν 2024 · Amplification and/or overexpression of ERBB2, the gene encoding HER2, can be found in 15–20% of invasive breast cancers and is associated with an aggressive phenotype and poor clinical outcomes.
3 Μαΐ 2024 · The drug trastuzumab deruxtecan (Enhertu) can now be used to treat a wide variety of cancers, thanks to a new approval from the Food and Drug Administration (FDA).
14 Ιαν 2023 · Although an interim analysis of a key secondary endpoint, this updated overall survival analysis of the DESTINY-Breast03 trial confirms trastuzumab deruxtecan in the second-line treatment of patients with HER2-postitive metastatic breast cancer.
25 Οκτ 2023 · HER2CLIMB study demonstrated improved survival outcomes in heavily pretreated patients with advanced or metastatic HER2 positive breast cancer, after at least 2 prior anti HER2 treatment regimens, including patients with active brain metastases, providing new treatment option for this difficult to treat population.
19 Οκτ 2021 · In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show.
17 Νοε 2023 · The PATRICIA study (NCT02536339) examined the efficacy and safety of pertuzumab plus high-dose trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) with progressive...
